Compounds > dynole 34-2
Page last updated: 2024-11-13

dynole 34-2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dynole 34-2: a dynamin inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44157463
CHEMBL ID483059
SCHEMBL ID14635693
MeSH IDM000605754

Synonyms (17)

Synonym
2-cyano-n-octyl-3-(1-(3-dimethylaminopropyl)-1h-indol-3-yl)-acrylamide
bdbm50268295
CHEMBL483059 ,
1128165-88-7
dynole 34-2
2-cyano-3-[1-[3-(dimethylamino)propyl]-1h-indol-3-yl]-n-octyl-2-propenamide
SCHEMBL14635693
AKOS024458042
J-002847
2-cyano-3-(1-(3-(dimethylamino)propyl)-1h-indol-3-yl)-n-octylacrylamide
AS-16432
dynole-34-2
A898928
HY-107545
(e)-2-cyano-3-[1-[3-(dimethylamino)propyl]indol-3-yl]-n-octylprop-2-enamide
CS-0028852
AKOS040745181
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dynamin-2Homo sapiens (human)IC50 (µMol)5.00005.00005.00005.0000AID722104
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)IC50 (µMol)9.40000.00051.33138.0000AID722103; AID722104
Dynamin-1Homo sapiens (human)IC50 (µMol)5.00003.15004.17335.0000AID375134
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (31)

Processvia Protein(s)Taxonomy
G2/M transition of mitotic cell cycleDynamin-2Homo sapiens (human)
regulation of DNA-templated transcriptionDynamin-2Homo sapiens (human)
post-Golgi vesicle-mediated transportDynamin-2Homo sapiens (human)
endocytosisDynamin-2Homo sapiens (human)
receptor-mediated endocytosisDynamin-2Homo sapiens (human)
phagocytosisDynamin-2Homo sapiens (human)
autophagyDynamin-2Homo sapiens (human)
centrosome cycleDynamin-2Homo sapiens (human)
signal transductionDynamin-2Homo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIDynamin-2Homo sapiens (human)
regulation of axon extensionDynamin-2Homo sapiens (human)
receptor internalizationDynamin-2Homo sapiens (human)
transferrin transportDynamin-2Homo sapiens (human)
positive regulation of apoptotic processDynamin-2Homo sapiens (human)
stress fiber assemblyDynamin-2Homo sapiens (human)
positive regulation of DNA-templated transcriptionDynamin-2Homo sapiens (human)
synaptic vesicle transportDynamin-2Homo sapiens (human)
neuron projection morphogenesisDynamin-2Homo sapiens (human)
protein polymerizationDynamin-2Homo sapiens (human)
membrane organizationDynamin-2Homo sapiens (human)
actin filament bundle organizationDynamin-2Homo sapiens (human)
membrane tubulationDynamin-2Homo sapiens (human)
vesicle scissionDynamin-2Homo sapiens (human)
negative regulation of membrane tubulationDynamin-2Homo sapiens (human)
synaptic vesicle budding from presynaptic endocytic zone membraneDynamin-2Homo sapiens (human)
endocytosisDynamin-1Homo sapiens (human)
receptor-mediated endocytosisDynamin-1Homo sapiens (human)
endosome organizationDynamin-1Homo sapiens (human)
modulation of chemical synaptic transmissionDynamin-1Homo sapiens (human)
protein homooligomerizationDynamin-1Homo sapiens (human)
protein homotetramerizationDynamin-1Homo sapiens (human)
regulation of vesicle sizeDynamin-1Homo sapiens (human)
clathrin coat assembly involved in endocytosisDynamin-1Homo sapiens (human)
vesicle scissionDynamin-1Homo sapiens (human)
receptor internalizationDynamin-1Homo sapiens (human)
synaptic vesicle budding from presynaptic endocytic zone membraneDynamin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
GTPase activityDynamin-2Rattus norvegicus (Norway rat)
GTPase activityDynamin-2Homo sapiens (human)
protein bindingDynamin-2Homo sapiens (human)
GTP bindingDynamin-2Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingDynamin-2Homo sapiens (human)
microtubule bindingDynamin-2Homo sapiens (human)
SH3 domain bindingDynamin-2Homo sapiens (human)
enzyme bindingDynamin-2Homo sapiens (human)
RNA bindingDynamin-1Homo sapiens (human)
GTPase activityDynamin-1Homo sapiens (human)
protein bindingDynamin-1Homo sapiens (human)
GTP bindingDynamin-1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingDynamin-1Homo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate bindingDynamin-1Homo sapiens (human)
GDP bindingDynamin-1Homo sapiens (human)
protein kinase bindingDynamin-1Homo sapiens (human)
identical protein bindingDynamin-1Homo sapiens (human)
protein homodimerization activityDynamin-1Homo sapiens (human)
microtubule bindingDynamin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
cytosolDynamin-2Rattus norvegicus (Norway rat)
plasma membraneDynamin-2Rattus norvegicus (Norway rat)
growth coneDynamin-2Homo sapiens (human)
Golgi membraneDynamin-2Homo sapiens (human)
phagocytic cupDynamin-2Homo sapiens (human)
uropodDynamin-2Homo sapiens (human)
podosomeDynamin-2Homo sapiens (human)
endosomeDynamin-2Homo sapiens (human)
Golgi apparatusDynamin-2Homo sapiens (human)
centrosomeDynamin-2Homo sapiens (human)
centrioleDynamin-2Homo sapiens (human)
cytosolDynamin-2Homo sapiens (human)
microtubuleDynamin-2Homo sapiens (human)
plasma membraneDynamin-2Homo sapiens (human)
clathrin-coated pitDynamin-2Homo sapiens (human)
focal adhesionDynamin-2Homo sapiens (human)
postsynaptic densityDynamin-2Homo sapiens (human)
clathrin-coated vesicleDynamin-2Homo sapiens (human)
midbodyDynamin-2Homo sapiens (human)
endocytic vesicle membraneDynamin-2Homo sapiens (human)
phagocytic vesicle membraneDynamin-2Homo sapiens (human)
neuron projectionDynamin-2Homo sapiens (human)
postsynaptic membraneDynamin-2Homo sapiens (human)
recycling endosomeDynamin-2Homo sapiens (human)
extracellular exosomeDynamin-2Homo sapiens (human)
presynapseDynamin-2Homo sapiens (human)
synapseDynamin-2Homo sapiens (human)
cytoplasmDynamin-2Homo sapiens (human)
microtubuleDynamin-2Homo sapiens (human)
plasma membraneDynamin-2Homo sapiens (human)
photoreceptor inner segmentDynamin-1Homo sapiens (human)
plasma membraneDynamin-1Homo sapiens (human)
clathrin-coated pitDynamin-1Homo sapiens (human)
endocytic vesicleDynamin-1Homo sapiens (human)
chromaffin granuleDynamin-1Homo sapiens (human)
cell projectionDynamin-1Homo sapiens (human)
extracellular exosomeDynamin-1Homo sapiens (human)
photoreceptor ribbon synapseDynamin-1Homo sapiens (human)
presynapseDynamin-1Homo sapiens (human)
presynaptic endocytic zone membraneDynamin-1Homo sapiens (human)
glutamatergic synapseDynamin-1Homo sapiens (human)
membrane coatDynamin-1Homo sapiens (human)
plasma membraneDynamin-1Homo sapiens (human)
synapseDynamin-1Homo sapiens (human)
microtubuleDynamin-1Homo sapiens (human)
cytoplasmDynamin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID722105Cytotoxicity against human HeLa cells at 30 uM after 8 hrs by trypan blue exclusion assay2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Development of second-generation indole-based dynamin GTPase inhibitors.
AID722103Inhibition of rat full length His6-tagged dyn2 using phosphatidylserine as substrate after 90 mins by malachite green GTPase assay in presence of GTP2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Development of second-generation indole-based dynamin GTPase inhibitors.
AID375135Toxicity against human fibroblasts assessed as cell viability at 10 uM by trypan blue exclusion method2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Inhibition of dynamin mediated endocytosis by the dynoles--synthesis and functional activity of a family of indoles.
AID375134Inhibition of dynamin 1-mediated endocytosis internalization of Tf-A594 in human U2OS cells pretreated for 30 mins2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Inhibition of dynamin mediated endocytosis by the dynoles--synthesis and functional activity of a family of indoles.
AID375133Toxicity against human U2OS cells assessed as effect on cell morphology after 30 mins2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Inhibition of dynamin mediated endocytosis by the dynoles--synthesis and functional activity of a family of indoles.
AID375132Inhibition of dynamin 2-mediated endocytosis internalization of Texas red-transferrin in human U2OS cells at 100 uM pretreated for 30 mins2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Inhibition of dynamin mediated endocytosis by the dynoles--synthesis and functional activity of a family of indoles.
AID722102Inhibition of sheep full length dyn1 using phosphatidylserine as substrate after 10 mins by malachite green GTPase assay in presence of GTP2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Development of second-generation indole-based dynamin GTPase inhibitors.
AID375130Inhibition of dynamin 2-mediated endocytosis internalization of Texas red-transferrin in human U2OS cells at 30 uM pretreated for 30 mins2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Inhibition of dynamin mediated endocytosis by the dynoles--synthesis and functional activity of a family of indoles.
AID375128Inhibition of sheep brain dynamin 1 GTPase activity by malachite green GTPase assay2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Inhibition of dynamin mediated endocytosis by the dynoles--synthesis and functional activity of a family of indoles.
AID375131Inhibition of dynamin 2-mediated endocytosis internalization of Texas red-transferrin in human U2OS cells at 20 uM pretreated for 30 mins2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Inhibition of dynamin mediated endocytosis by the dynoles--synthesis and functional activity of a family of indoles.
AID375136Toxicity against mouse NIH/3T3 cells assessed as cell viability at 10 uM by trypan blue exclusion method2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Inhibition of dynamin mediated endocytosis by the dynoles--synthesis and functional activity of a family of indoles.
AID722104Inhibition of dyn2 in human U2OS cells assessed as clathrin-mediated endocytosis of Tfn after 30 mins2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Development of second-generation indole-based dynamin GTPase inhibitors.
AID722101Selectivity ratio of IC50 for sheep dyn1 receptor to IC50 for rat dyn2 receptor2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Development of second-generation indole-based dynamin GTPase inhibitors.
AID722106Inhibition of sheep dyn1 after 30 mins by malachite green GTPase assay in presence of GTP2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Development of second-generation indole-based dynamin GTPase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's5 (55.56)24.3611
2020's3 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.97 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index19.78 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
bisindolylmaleimide i
bisindolylmaleimide I: a bis(indolyl)maleimide		2.0510
2-(1-(2-(1-methylpyrrolidino)ethyl)-1h-indol-3-yl)maleimide
bisindolylmaleimide II: protein kinase C inhibitor; see also bisindolylmaleimide I		2.0510
2-naphthol
2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.		2.5120naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
neuropeptide y
Neuropeptide Y: A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.		2.1110
glucagon-like peptide 1
Glucagon-Like Peptide 1: A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.		2.3110
peptide yy
Peptide YY: A 36-amino acid peptide produced by the L cells of the distal small intestine and colon. Peptide YY inhibits gastric and pancreatic secretion.. peptide YY : A 36-membered human gut polypeptide consisting of Tyr, Pro, Ile, Lys, Pro, Glu, Ala, Pro, Gly, Glu, Asp, Ala, Ser, Pro, Glu, Glu, Leu, Asn, Arg, Tyr, Tyr, Ala, Ser, Leu, Arg, His, Tyr, Leu, Asn, Leu, Val, Thr, Arg, Gln, Arg and Tyr-NH2 residues joined in sequence.		2.3110
dyngo-4a
[no description available]		2.5120aromatic alcoholEC 3.6.5.5 (dynamin GTPase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Granulocytic Leukemia
[description not available]		02.2510
Acute Disease
Disease having a short and relatively severe course.		02.2510
Leukemia, Myeloid
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.		02.2510
Benign Neoplasms, Brain
[description not available]		02.2110
Glial Cell Tumors
[description not available]		02.2110
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.2110
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.2110